Locations:
Results based on early data from clinical trial
Early results presented at ASCO 2018
New mRCC medication regimen effective and well tolerated
Drug stimulates an immune response to survivin
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Many genetic alterations were related to other malignancies
Phase 1b trial shows good response rate
Individual tumor DNA may be key
Cleveland Clinic urologist performs first procedure in Europe
Response to larotrectinib “almost miraculous”
Established lymphoma/leukemia therapy also targets glioma stem cells
Advertisement
Advertisement
Search